-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Decreases By 11.6%
Short Interest in Bright Minds Biosciences Inc. (NASDAQ:DRUG) Decreases By 11.6%
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 824,900 shares, a decline of 11.6% from the November 15th total of 932,900 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,430,000 shares, the short-interest ratio is presently 0.6 days.
Institutional Investors Weigh In On Bright Minds Biosciences
A hedge fund recently bought a new stake in Bright Minds Biosciences stock. Jane Street Group LLC acquired a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
Get Bright Minds Biosciences alerts:Bright Minds Biosciences Trading Down 3.2 %
Shares of DRUG stock opened at $0.91 on Tuesday. The stock has a 50 day simple moving average of $1.01 and a 200 day simple moving average of $1.14. Bright Minds Biosciences has a 1 year low of $0.75 and a 1 year high of $4.75.
About Bright Minds Biosciences
(Get Rating)Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Featured Stories
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) was the target of a significant decline in short interest in the month of November. As of November 30th, there was short interest totalling 824,900 shares, a decline of 11.6% from the November 15th total of 932,900 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,430,000 shares, the short-interest ratio is presently 0.6 days.
光明之心生物科學公司(納斯達克：毒品獲得評級)是空頭股數11月份大幅下跌的目標。截至11月30日，空頭股數共有824,900股，較11月15日的932,900股下降11.6%。目前，該股11.0%的股份被賣空。以日均成交量1,430,000股計算，目前短息比率為0.6天。
Institutional Investors Weigh In On Bright Minds Biosciences
機構投資者看好Bright Minds生物科學
A hedge fund recently bought a new stake in Bright Minds Biosciences stock. Jane Street Group LLC acquired a new stake in shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 24,701 shares of the company's stock, valued at approximately $37,000. Jane Street Group LLC owned approximately 0.21% of Bright Minds Biosciences at the end of the most recent reporting period. Institutional investors own 4.03% of the company's stock.
一家對沖基金最近購買了Bright Minds Biosciences股票的新股份。建恩街集團有限公司(Jane Street Group LLC)根據其最近提交給美國證券交易委員會(SEC)的13F檔案，在第一季度收購了光明心靈生物科學公司(Bright Minds Biosciences Inc.)(納斯達克代碼：Drug-Get Rating)的新股。該基金購買了24,701股該公司的股票，價值約37,000美元。在最近一次報告期結束時，建恩街集團擁有Bright Minds Biosciences約0.21%的股份。機構投資者持有該公司4.03%的股份。
Bright Minds Biosciences Trading Down 3.2 %
光明之心生物科學公司股價下跌3.2%
Shares of DRUG stock opened at $0.91 on Tuesday. The stock has a 50 day simple moving average of $1.01 and a 200 day simple moving average of $1.14. Bright Minds Biosciences has a 1 year low of $0.75 and a 1 year high of $4.75.
週二，藥品類股開盤報0.91美元。該股的50日簡單移動均線切入位為1.01美元，200日簡單移動均線切入位為1.14美元。Bright Minds Biosciences的一年低點為0.75美元，一年高位為4.75美元。
About Bright Minds Biosciences
關於Bright Minds生物科學
Bright Minds Biosciences Inc, a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry.
Bright Minds Biosciences Inc是一家臨床前生物科學公司，開發5-羥色胺(5-HT)藥物，以改善嚴重和改變生活的疾病患者的生活。該公司的選擇性5-羥色胺受體激動劑組合包括5-HT2C、5-HT2A和5-HT2C/A，用於治療癲癇、疼痛和神經精神病學。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Bright Minds Biosciences (DRUG)
- Will Tesla Shares Rally If Musk Steps Down From Twitter?
- 5 Down But Not Out Stocks To Watch For 2023
- Can Chewy Fetch Double Digit Gains in 2023?
- Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
- Madrigal Pharmaceuticals Stock Is Up 200% In One Day, Here's Why
- 免費獲取StockNews.com關於Bright Minds生物科學(藥物)的研究報告
- 如果馬斯克退出Twitter，特斯拉的股價會上漲嗎？
- 2023年值得關注的5個下跌但不是下跌的股票
- Chewy能否在2023年獲得兩位數的增長？
- 禮來公司預計將實現持久增長，儘管面臨眼前的挑戰
- Madrigal製藥公司的股票在一天內上漲了200%，原因如下
Receive News & Ratings for Bright Minds Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bright Minds Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Bright Minds生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bright Minds Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧